Correction: Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019

Ther Innov Regul Sci. 2023 Jan;57(1):48. doi: 10.1007/s43441-022-00452-7.

Authors

Mei Kohama¹, Takahiro Nonaka², Yoshiaki Uyama², Chieko Ishiguro³

Affiliations

¹ Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
² Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
³ Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Science, National Center for Global Health and Medicine, 1-21-1, Toyama Shinjuku-ku, Tokyo, 162-8655, Japan. chishiguro@hosp.ncgm.go.jp.

PMID: 36008628
DOI: 10.1007/s43441-022-00452-7

No abstract available

Publication types

Published Erratum